These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11577831)

  • 1. Aspirin and the prevention of ischemic heart disease. A Socratic dialogue between a cardiologist, a clinical pharmacologist and an expert of blood platelets.
    de Gaetano G
    Ital Heart J; 2001 Aug; 2(8):582-8. PubMed ID: 11577831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin in ischemic heart disease--an overview.
    Rao GH; Rao AS; White JG
    Indian Heart J; 1993; 45(2):73-9. PubMed ID: 8365757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of clopidogrel in the management of ischemic heart disease.
    Galla JM; Lincoff AM
    Curr Opin Cardiol; 2007 Jul; 22(4):273-9. PubMed ID: 17556877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Should individuals without evidence of coronary disease and with risk factors receive continuous treatment with aspirin? Arguments against].
    López de Sá E
    Rev Esp Cardiol; 1996 Nov; 49(11):788-92. PubMed ID: 9082487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
    Arjomand H; Cohen M; Ezekowitz MD
    J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acetylsalicylic acid (ASA) resistance in patients with ischemic heart disease (IHD) as bioindicator of the treatment strategy].
    Malý J; Pecka M; Gregor J; Dulícek P; Blazek M; Malý R; Pudil R; Bláha M
    Cas Lek Cesk; 2005; 144 Suppl 3():23-9. PubMed ID: 16335259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibalpha is overrepresented in patients with recurrent stroke regardless of aspirin therapy.
    Cervera A; Tàssies D; Obach V; Amaro S; Reverter JC; Chamorro A
    Cerebrovasc Dis; 2007; 24(2-3):242-6. PubMed ID: 17630485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
    Hankey GJ
    Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet drugs for ischemic stroke prevention.
    Leys D; Balucani C; Cordonnier C
    Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the risk: heart disease, stroke and aspirin.
    Elwood PC
    J Med Assoc Thai; 2001 Aug; 84(8):1164-74. PubMed ID: 11758854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.